CSIMarket
 


National Research Corporation  (NRC)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 

NRC's Net Income Growth by Quarter and Year

National Research's Net Income results by quarter and year




NRC Net Income (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
IV Quarter December - 8.86 6.64 9.63
III Quarter September - 7.88 8.30 9.66
II Quarter June - 7.27 8.32 8.94
I Quarter March 6.36 6.96 8.54 9.23
FY   6.36 30.97 31.80 37.46



NRC Net Income first quarter 2024 Y/Y Growth Comment
National Research Corporation reported decrease in Net Income in the first quarter 2024 by -8.64% to $ 6.36 millions, from the same quarter in 2023.
The decrease in the first quarter 2024 National Research Corporation's Net Income compares unfavorably to the Company's average Net Income increase of 11.58%.

Looking into first quarter 2024 results within Medical Laboratories industry 4 other companies have achieved higher Net Income growth. While National Research Corporation' s Net Income decline of -8.64% ranks overall at the positon no. 615 in the first quarter 2024.




NRC Net Income ( Y/Y Growth %) 2024
2023 2022 2021
IV Quarter December - 33.43 % -31.05 % 17.3 %
III Quarter September - -5.06 % -14.08 % 0.84 %
II Quarter June - -12.62 % -6.94 % 15.8 %
I Quarter March -8.64 % -18.5 % -7.48 % -21.51 %
FY   - -2.61 % -15.11 % 0.51 %

Financial Statements
National Research's first quarter 2024 Net Income $ 6.36 millions NRC's Income Statement
National Research's first quarter 2023 Net Income $ 6.96 millions Quarterly NRC's Income Statement
New: More NRC's historic Net Income Growth >>


NRC Net Income (Quarter on Quarter Growth %)

2024
2023 2022 2021
IV Quarter December - 12.44 % -20 % -0.31 %
III Quarter September - 8.39 % -0.24 % 8.05 %
II Quarter June - 4.45 % -2.58 % -3.14 %
I Quarter March -28.23 % 4.82 % -11.32 % 12.42 %
FY (Year on Year)   - -2.61 % -15.11 % 0.51 %




Net Income first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #5
Healthcare Sector #50
Overall #615

Net Income Y/Y Growth Statistics
High Average Low
137.12 % 11.58 % -19.29 %
(Sep 30 2017)   (Jun 30 2023)
Net Income first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #5
Healthcare Sector #50
Overall #615
Net Income Y/Y Growth Statistics
High Average Low
137.12 % 11.58 % -19.29 %
(Sep 30 2017)   (Jun 30 2023)

Net Income by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

National Research's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
56.92 % 1.38 % -34.37 %
(Dec 31 2017)  


NRC's I. Quarter Q/Q Net Income Comment
In the I. Quarter 2024 National Research Corporation reported fall in Net Income from the previous quarter by -28.23% to $ 6.36 millions, from $ 8.86 millions achived a quarter before.

Those seasonal influence that commonly fuel I. Quarter 2024 performance, could not rescue the I. Quarter for the National Research Corporation, Carolina Vieira, a business expert from Paris wrote, she mentioned some caution towards National Research's perspective.

Within Medical Laboratories industry 4 other companies have achieved higher Net Income quarter on quarter growth. While National Research's Net Income growth quarter on quarter, overall rank is 786.


Net Income Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #5
Healthcare Sector #49
Overall #786
Net Income Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #5
Healthcare Sector #49
Overall #786
Net Income Q/Q Growth Statistics
High Average Low
56.92 % 1.38 % -34.37 %
(Dec 31 2017)  


NRC's I. Quarter Q/Q Net Income Comment
In the I. Quarter 2024 National Research Corporation realized fall in Net Income sequentially by -28.23% to $ 6.36 millions, from $ 8.86 millions achived in the previous quarter.

Although seasonal factors which commonly energize I. Quarter 2024 Net Income, it simply has not been enough to recover Medical Laboratories's company achievement, Carolina Vieira, a business expert from Paris said and wrote that average sequential Net Income growth is at 1.38% for NRC.

Within Medical Laboratories industry 4 other companies have achieved higher Net Income quarter on quarter growth. While National Research's Net Income growth quarter on quarter, overall rank is 786.


National Research's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Mar 31 2024)
12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
Cumulative Net Income 12 Months Ending $ 30.37 $ 30.97 $ 28.75 $ 29.18 $ 30.23
Y / Y Net Income Growth (TTM) 0.47 % -2.61 % -17.35 % -19.29 % -17.81 %
Year on Year Net Income Growth Overall Ranking # 752 # 1013 # 851 # 759 # 760
Seqeuential Net Income Change (TTM) -1.95 % 7.71 % -1.45 % -3.47 % -4.95 %
Seq. Net Income Growth (TTM) Overall Ranking # 615 # 928 # 859 # 792 # 869




Cumulative Net Income growth Comment
Although National Research's Annual Net Income growth year on year were below company's average 11.58% , Net Income announced in the Mar 31 2024 period, show improvement in Net Income trend, to cumulative trailing twelve month growth of 0.47% year on year, from -2.61% in Dec 31 2023.

In the Healthcare sector 56 other companies have achieved higher trailing twelve month Net Income growth. While Total ranking has impoved so far to 752, from total ranking in previous quarter at 1013.

Net Income TTM Q/Q Growth Statistics
High Average Low
137.12 %
11.58 %
-19.29 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 5
Healthcare Sector # 57
Overall # 752

Net Income TTM Y/Y Growth Statistics
High Average Low
137.12 %
11.58 %
-19.29 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 5
Sector # 50
S&P 500 # 615
Cumulative Net Income growth Comment
Although National Research's Annual Net Income growth year on year were below company's average 11.58% , Net Income announced in the Mar 31 2024 period, show improvement in Net Income trend, to cumulative trailing twelve month growth of 0.47% year on year, from -2.61% in Dec 31 2023.

In the Healthcare sector 56 other companies have achieved higher trailing twelve month Net Income growth. While Total ranking has impoved so far to 752, from total ranking in previous quarter at 1013.

Net Income TTM Q/Q Growth Statistics
High Average Low
137.12 %
11.58 %
-19.29 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 5
Healthcare Sector # 57
Overall # 752

Net Income TTM Y/Y Growth Statistics
High Average Low
137.12 %
11.58 %
-19.29 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 5
Sector # 50
S&P 500 # 615




Other Net Income Growth
Medical Laboratories Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
NRC's Net Income Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for NRC's Competitors
Net Income Growth for National Research's Suppliers
Net Income Growth for NRC's Customers

You may also want to know
NRC's Annual Growth Rates NRC's Profitability Ratios NRC's Asset Turnover Ratio NRC's Dividend Growth
NRC's Roe NRC's Valuation Ratios NRC's Financial Strength Ratios NRC's Dividend Payout Ratio
NRC's Roa NRC's Inventory Turnover Ratio NRC's Growth Rates NRC's Dividend Comparisons



Companies with similar Net Income fall for the quarter ending Mar 31 2024 within Healthcare SectorY/Y Change %Net Income for the quarter ending Mar 31 2024
Iqvia Holdings Inc -0.35%$ -0.346 millions
Cadre Holdings inc -1.06%$ -1.057 millions
Exelixis Inc -1.95%$ -1.950 millions
Quest Diagnostics Inc-4.15%$ -4.147 millions
Progyny Inc -4.41%$ -4.412 millions
3m Company-4.89%$ -4.893 millions
Mettler Toledo International Inc-5.79%$ -5.794 millions
Utah Medical Products Inc-6.12%$ -6.122 millions
Abbott Laboratories-7.06%$ -7.056 millions
Entera Bio Ltd -7.90%$ -7.900 millions
National Research Corporation-8.69%$ -8.688 millions
Regeneron Pharmaceuticals Inc -11.71%$ -11.714 millions
Baxter International Inc -13.33%$ -13.333 millions
Phibro Animal Health Corporation-16.30%$ -16.302 millions
West Pharmaceutical Services Inc -17.64%$ -17.643 millions
Atrion Corporation-19.89%$ -19.885 millions
Tenx Keane Acquisition-19.93%$ -19.927 millions
Catalyst Pharmaceuticals Inc -21.28%$ -21.283 millions
American Shared Hospital Services-35.00%$ -35.000 millions
Amedisys Inc-41.41%$ -41.411 millions
Dariohealth Corp -44.05%$ -44.055 millions
Fonar Corporation-44.64%$ -44.638 millions
Envista Holdings Corporation-46.12%$ -46.119 millions
Viatris Inc -49.31%$ -49.310 millions
Pro dex Inc -50.11%$ -50.114 millions
Avantor Inc -50.29%$ -50.288 millions
Ir med Inc -51.33%$ -51.333 millions
Privia Health Group Inc -52.26%$ -52.265 millions
Orgenesis Inc -57.20%$ -57.202 millions
Oramed Pharmaceuticals Inc -57.52%$ -57.519 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com